Molecular mechanisms of diabetic vascular complications.
Diabetic complications are the major causes of morbidity and mortality in patients with diabetes. Microvascular complications include retinopathy, nephropathy and neuropathy, which are leading causes of blindness, end-stage renal disease and various painful neuropathies; whereas macrovascular complications involve atherosclerosis related diseases, such as coronary artery disease, peripheral vascular disease and stroke. Diabetic complications are the result of interactions among systemic metabolic changes, such as hyperglycemia, local tissue responses to toxic metabolites from glucose metabolism, and genetic and epigenetic modulators. Chronic hyperglycemia is recognized as a major initiator of diabetic complications. Multiple molecular mechanisms have been proposed to mediate hyperglycemia's adverse effects on vascular tissues. These include increased polyol pathway, activation of the diacylglycerol/protein kinase C pathway, increased oxidative stress, overproduction and action of advanced glycation end products, and increased hexosamine pathway. In addition, the alterations of signal transduction pathways induced by hyperglycemia or toxic metabolites can also lead to cellular dysfunctions and damage vascular tissues by altering gene expression and protein function. Less studied than the toxic mechanisms, hyperglycemia might also inhibit the endogenous vascular protective factors such as insulin, vascular endothelial growth factor, platelet-derived growth factor and activated protein C, which play important roles in maintaining vascular homeostasis. Thus, effective therapies for diabetic complications need to inhibit mechanisms induced by hyperglycemia's toxic effects and also enhance the endogenous protective factors. The present review summarizes these multiple biochemical pathways activated by hyperglycemia and the potential therapeutic interventions that might prevent diabetic complications. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.00018.x, 2010).
Dianne Nunnally Hoppes Laboratory for Diabetes Complications, Joslin Diabetes Center, Boston, MA, USA.
Munehiro
M
Kitada
Dianne Nunnally Hoppes Laboratory for Diabetes Complications, Joslin Diabetes Center, Boston, MA, USA.
Zhaoyun
Z
Zhang
Dianne Nunnally Hoppes Laboratory for Diabetes Complications, Joslin Diabetes Center, Boston, MA, USA.
Akira
A
Mima
Dianne Nunnally Hoppes Laboratory for Diabetes Complications, Joslin Diabetes Center, Boston, MA, USA.
George L
GL
King
Diabetes mellitus; Diabetic complications; Endogenous protective factors